IMGN has initiated a new HOLD rating as of 02/07/2011. The rating change was due to the Technical Model which has improved to the favorable zone while the Fundamental Risk Model has remained in the high risk zone. Stocks that have a combined model reading that is neutral, but was previously negative, will have a HOLD rating until a positive or negative combined model reading is produced. Investors should wait until a new BUY or SELL signal is given before taking new action on the stock. While the current rating is neutral for IMGN there are some encouraging signs for the stock. - IMGN's Earnings Yield relative to the Standard and Poor’s 500 Earnings Yield is bullish. Evaluation of this relative measure suggests IMGN is more reasonably priced compared to the broad market. - Earnings Momentum for IMGN is bullish. The momentum, or growth rate, of a company's earnings is a widely watched indicator of the company's success, and translates directly to increases in shareholder value. - IMGN's price action, as measured by indicators such as moving averages that provide an objective measure of trend direction by smoothing the price data, is currently showing strength. - IMGN's volume action, as measured by indicators applied to trading volume, is currently showing strength. Volume indicators are used to confirm the strength of price trends. Lack of confirmation may warn of a reversal. There are some negative indications for IMGN which are concerns for the current neutral rating. - The performance of IMGN has historically been correlated with the external factor - Advisory Sentiment. This indicator is based on opinion surveys of stock market advisory services. This indicator works very well in identifying excessive emotional levels in advisory groups, which correspond well to general market peaks and troughs. The current sentiment environment is bearish for IMGN. - IMGN's Sales / Price (Sales Yield) is bearish, showing overvaluation based on its sales yield relative to the previous five years. The sales yield shows what investors are willing to pay for top line (sales) growth for each dollar worth of investment.
Useless. Does not apply. But what still concerns is that very low royalty percentage, estimated at 4%. Is this indicative of lame negotiating by IMGN? I still don't understand why it was so low, for something with so much value for Roche.
Wow, this analysis is almost useless. There is not a single indication that they did the slightest bit of research or reading on what Immunogen even does. I don't even know if they understand that this is a biotech company. Why do they even bother?
Ned Davis is a quant modeling based research shop, their methods are not relevant, or useful for evaluating development stage biotech firms where one is trying to estimate the future market shares and revenues for products that are yet to be approved. ND is looking at BS and IS statements that are in the rear view mirror. I am surprised their technical indicators were positive after the big dip, most technicians would find that type of drop troubling. The chart is starting to stabelize/improve, but looks like an oversold bounce. I don't find the current technicals "strong", more volume on the up days is needed. This stock is very difficult to predict, so for now $8-$10 is the way to play it for technical trading. LT it looks very undervalued and promising IMO.